Compare PVH & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PVH | ACAD |
|---|---|---|
| Founded | 1881 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.3B |
| IPO Year | 1994 | 2000 |
| Metric | PVH | ACAD |
|---|---|---|
| Price | $76.21 | $29.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 22 |
| Target Price | ★ $90.53 | $30.55 |
| AVG Volume (30 Days) | 864.3K | ★ 1.8M |
| Earning Date | 06-03-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.16% | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | ★ 1.90 | 0.20 |
| Revenue | ★ $8,950,200,000.00 | $726,437,000.00 |
| Revenue This Year | $1.89 | $18.80 |
| Revenue Next Year | $1.86 | $11.70 |
| P/E Ratio | ★ $41.32 | $147.90 |
| Revenue Growth | 3.44 | ★ 40.45 |
| 52 Week Low | $59.60 | $19.69 |
| 52 Week High | $100.75 | $30.96 |
| Indicator | PVH | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 43.83 | N/A |
| Support Level | $69.08 | N/A |
| Resistance Level | $79.95 | N/A |
| Average True Range (ATR) | 2.56 | 0.00 |
| MACD | -0.73 | 0.00 |
| Stochastic Oscillator | 24.19 | 0.00 |
PVH designs and markets branded apparel in more than 40 countries. Its key fashion categories include men's dress shirts, ties, sportswear, underwear, and jeans. Its two designer brands, Calvin Klein and Tommy Hilfiger, now generate practically all its revenue after its recent disposition of most of its smaller brands. PVH operates e-commerce sites, roughly 1,400 standalone stores, and about 1,500 shop-in-shops and concessions. The firm also licenses its brands to third parties and distributes its merchandise through department stores and other wholesale accounts. PVH traces its history to 1881 and is based in New York City.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.